NCT07050160
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Enrolling by Invitation
Not specifiedAges 18–67ObservationalLexeo Therapeutics
~10 participants
Updated 2025-11-12 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).
Measured over 4 years
Conditions
Where it's being run
1 sites across 1 statesMichigan1
Study leadership
- Lexeo Clinical Trials · STUDY_DIRECTOR · Lexeo Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants who received LX2020 in study LX2020-01
Exclusion
Concurrent enrollment in any other clinical investigation involving use of an investigational agent.
What this trial measures
- Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).4 years
Evaluation of Safety and Tolerability of LX2020